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Summary Calcipotriol and corticosteroids, two therapy modalities frequently prescribed in the treatment of
psoriasis, are often used in combination. The aim of the present study was to determine whether the 
cell biological response pattern of concurrent use of calcipotriol and corticosteroids is different from 
calcipotriol monotherapy. Forty patients with chronic plaque psoriasis were divided at random in 
four parallel groups and treated for 8 weeks with: (1) calcipotriol cream (50 /ig/g once daily): (2) 
calcipotriol cream twice daily: (3) calcipotriol and clobetasone 17-butyrate (0*5 mg/g) creams; and 
(4) calcipotriol and betamethasone 17-valerate (lm g/g) creams. Before and after treatment 
keratotome biopsies were taken and single cell suspensions prepared for flow cytometric analysis. 
Flow cytometric multiparameter quantification of markers for proliferation (TO-PRO-3), differentia­
tion (antikeratin 1 0 ) and inflammation (antivimentin) was used to evaluate all four therapy 
modalities.
A statistically significant decrease of the percentage of basal cells in S- and C^M-phase (prolifera­
tion) was obtained with all therapy modalities, except for calcipotriol monotherapy applied once 
daily. A significant reduction of the number of vimentin-positive cells (non-keratinocytes) was 
observed following combined treatment with calcipotriol and clobetasone butyrate. In contrast, 
monotherapy with calcipotriol had virtually no effect on the number of vimentin-positive cells.
It can be concluded that: (i) calcipotriol monotherapy, applied once daily was less antiproliferative 
compared with twice daily applications of calcipotriol or the combined treatment with corticosteroids 
and that (ii) the combination of calcipotriol and corticosteroids proved to have a marked effect on the 
percentage of non-keratinocytes, in contrast to the modest effect of calcipotriol.
Vitamin D j analogues interfere with various c 
istics of the psoriatic plaque: epidermal 
tion, impaired differentiation and cutaneous 
mation. In vitro studies demonstrated that c
inhibits proliferation and stimulates differentiation in 
cultured human keratinocytes. Several inflammatory
are modulated by calcipotriol.1“ 5 Inprocesses VIVO,
topical application of calcipotriol to psoriatic plaques 
resulted in decreased epidermal DNA synthesis and a 
shift of the expression pattern of epidermal cytokeratins 
towards normalization.6' 9 Furthermore, calcipotriol
10has been reported to influence different cytokines 
and to change the numbers of several immunocytes 
(polymorphonuclear leucocytes, CD la  positive cells, T
s) in psoriatic plaques.8,9,11,12 
epidermal proliferation has been 
reported to be the most conspicuous effect of 
treatment, whereas interference with inflammation is 
less marked.9 Using absolute counts, however, a sig­
nificant reduction of infiltrate cells in the epidermis has 
been claimed.8 In this respect it is of relevance that the 
combination of topical treatment with calcipotriol and 
low-dose systemic cyclosporin (2 mg/kg per day) proved 
to be a highly effective combination, indicating that the 
immunomodulating effect of cyclosporin might com-
relatively low immunosuppressive 
capacity of calcipotriol in vivo.1*
Double-blind, placebo-controlled studies showed that
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effective and saie antipsoriatic therapy can be obtained
■g/g
14.1 S In a
right-left comparison calcipotriol induced a signifi­
cantly larger reduction in PASI score compared with
participated in the study after informed consent. No 
systemic treatment had been used for at least 6 weeks. 
Excluded were patients who were pregnant, breastfeed­
ing or expected to become pregnant. After a wash-out
tion of PASI score was demonstr between
0-1 % betamethasone 17-valerate ointment.16 In a par- period of 2 weeks, in which only an emollient 
allel group study no significant difference in the reduc- (Danatekt") was permitted, patients were at random
assigned to one of four therapy groups. These consisted 
of 8 weeks treatment with a morning application of 
calcipotriol cream 50 /¿g/g and an evening i 
of either (1 ) vehicle of calcipotriol cream, (2 ) calci
calcipotriol and betamethasone, but patients’ efficacy
1  n
assessment was significantly in favour of calcipotriol. 
Calcipotriol ointment was also more effective and better
1 waccepted than short-contact dithranol therapy.
ever, an important limitation of calcipotriol monother­
apy twice daily is the occurrence of irritative dermatitis 
in 10-20% of patients.19 Once daily application of 
calcipotriol might decrease side-effects while maintain­
ing clinical efficacy. Also concurrent use of topical 
calcipotriol and topical corticosteroids might reduce 
the frequency of irritative dermatitis while maintaining 
or even improving the clinical result. Recently, a large 
multicentre study was initiated to establish the clinical 
efficacy and tolerability of a once-daily schedule of 
calcipotriol treatment and a combination of calcipotriol 
with a low and a medium strength corticosteroid. The 
results of this study (Leo Pharmaceutical Products, 
Denmark, data on file) will be published as a full report.
The aim of the present study was to analyse the 
response pattern of psoriatic skin with respect to epi­
dermal proliferation (percentage basal cells in S- and 
G^M-phase), epidermal differentiation (percentage cells 
expressing the differentiation marker keratin 10 ) and 
cutaneous inflammation (relative number of vimentin 
positive cells) to various treatment schedules: (1 ) calci­
potriol cream once daily; (2 ) calcipotriol cream twice 
daily; (3) calcipotriol cream in combination with clobe­
tasone 17-butyrate (0*5 mg/g); or (4) calcipotriol cream 
in combination with betamethasone 17-valerate cream
se patterns were evaluated using
multiparameter 
technique with simultaneous quantification of DNA
md two filament in
epidermal single cell suspensions.20,21 Single cell sus­
pensions were prepared from skin samples of 40
patients who participated in the above-mentioned com­
parative double-blind parallel group multicentre study 
at the Department of Dermatology, Nijmegen.
Materials and methods
Patients and biopsies
Forty patients stable chronic plaque
cream 50 /¿g/g, ( 3 ) clobetasone butyrate cream 0\5 
or (4) betamethasone valerate cream 1 mg/g on psoriatic 
lesions of extremities and trunk. Assessment of clinical 
scores for erythema, induration and desquamation (five- 
point scale) and of the area of the psoriatic lesions 
was performed every 2 weeks. Patients were withdrawn 
from the study before 8 weeks treatment if all lesions 
had cleared. Before and after treatment in total two 
keratotome biopsies (thickness 0-4 mm, 2 cm2) were 
taken from the same test lesion for flow cytometric 
analysis.
Cell isolation procedure
Epidermal single cell suspensions were prepared as 
described before. 1 , the keratotome 
were incubated in phosphate-buffered saline (PBS) con-
0-2 5 mg/ml
U.S.A.) and 3*0
in
St Louis, 
(Sigma) for 30 
10% heat-min at 37 C. 
inactivated newborn calf serum (HINCS, Life Technol­
ogies Ltd, Paisley, U.K.) the dermis was separated from 
the epidermis with a fine forceps. The remaining epi­
dermis was gently mixed on a vortex to loosen the
, res i in a s
ding the horny layer, the suspension was centri- 
the supernatant removed and the cells fixed in
70% ice-cold ethanol. The cell suspension was stored at
20l'C until staining and flow cytometric analysis.
f/ proce i
Triple labelling was performed, using a DNA lluoro- 
chrome combined with two antibodies
mediate filaments. The procedure has been described by 
us in detail before.21 To assess proliferation, the DNA 
lluorochrome TO-PRO-3 iodide (TP 3,
Eugene, OR, U.S.A.) was used.20 TP3 i 
double-stranded DNA and permits measurement of the 
proliferative activity of cells by quantification of the 
percentage of cells in S- and (LM-phase. As TP3 also
dates with
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binds to RNA to some extent, it was used in combina-
tion with RNase. To inflammation Vim3B4
(Novocastra Laboratories Ltd, Newcastle upon Tyne, 
U.K.) was used. This I gG 2 a-type mouse monoclonal 
antibody stains vimentin, an intermediate
type protein which occurs in mesenchymal cells., 22 In
software percentages of vimentin- and keratin 1 0-posi- 
tive cells were calculated. Using Multicycle c 
(Phoenix Flow Systems, San Diego, CA, U.S.A.) the 
percentages of basal keratinocytes in S- and GiM- 
phase of the cell cycle (proliferation) were calculated 
from DNA histograms.
the study, PMNs, lymphocytes,
macrophages, and
were stained by Vim3B4. The IgGl-type mouse mono-
RKSE60
Maat
of Molecularclonal 
Biology,
was used as differentiation marker. RKSE60 is directed 
against keratin 10 , an intermediate filament-type pro­
tein th at is
2 3,24 r
in
Three-colour fluorescence was obtained 
with the lluorochromes fluorescein-isothiocyanate 
(FITC) and phycoerythrin (PE), which were conjugated 
to monoclonal goat antibodies against mouse lgG2a 
and mouse IgGl, respectively (Southern Biotechnology 
Associates, Birmingham, AL, U.S.A.), in combination 
with TP 3.
Statistical
Changes in the relative numbers of vimentin positive 
cells, keratin 10 positive keratinocytes and basal cells in 
S- and G2M-phase •e and #< were
paired /-test for means (two-tail), 
therapies were assessed using the 
two-sample i-test assuming equal variances (two-tail). 
Analysis of the correlation between clinical and How 
cytometric scores was performed by calculation of the 
Pearson correlation coefficient.
Results
5Approximately 1 -2  x 10 cells of the cell suspen­
sions were washed in PBS, filtered to remove clumps
and horny material, and resuspended in /¿I of a
for
solution with Vim3B4 diluted 1:50 and RKSE60 diluted 
1:15 in PBS. After incubation for 30 mill at room 
temperature in the dark, the cells were washed in 
containing 1 % HINCS, resuspended and incub 
15 min at 5"C in a solution of 500 /¿I PBS, c 
2 /¿I goat-antimouse-PE, 10 ¡A goat-antimouse-FITC, 
10 //I normal goat serum and 5 //,! HINCS. After a third
I was performed by addition 
of 300 /.d TP 3 (1 /imol/1 in PBS) and 50 /A RNase (1 mg/ 
ml in PBS) (Sigma, St Louis, MO, U.S.A.).
Flow cytometric analysis
The flow cytometric measurements and analysis were 
performed before the treatment codes were revealed.
From each sample 5 0 0 0 -1 0 ,0 0 0  gì
’ an EPICS1* Emeasured and ani How
Of 40 included patients 39 completed the present study. 
One subject was withdrawn at week 4 because of severe 
generalized itching and worsening of psoriasis. This 
patient had used calcipotriol cream twice daily for 3 
weeks. All four therapy regimens resulted in a statisti­
cally significant reduction of PAS I scores. Percentages 
were 50% (calcipotriol once daily, D), 64% (calcipotriol 
twice daily, DD), 58% (calcipotriol in combination with 
clobetasone, DC) and 55% (calcipotriol in combination 
with betamethasone, DB). Between the four therapies 
no statistically significant difference in the decrease of 
the PASI score could be demonstrated. Clearance of the 
test lesions was reached in 10 subjects: values for each 
therapy group were 2 (D), 1 (DD), 3 (DC) and 4 (DB). In 
live subjects even clearance of all lesions was reached. 
These patients all had used calcipotriol in combination 
with a corticosteroid (DC: 3, DB: 2).
cytometer (Coulter, Luton, U.K.) equipped with a dual 
laser system. PE and FITC were 
cooled argon ion laser (1 5 mW,
an í
nm). TP 3 was 
excited with a HeNe laser (10 mW, 633 nm). Fluores­
cence was measured using bandpass filters of 5 2 0 -5 3 0  
nm (green, FITC), 5 5 5 -5 9 5  nm (orange, PE) and 6 7 0 -  
680 nm (red, TP3). The area/peak ratio of the red signal 
(DNA) was used to discriminate between
id cells (clumps) and real single tetrt 1 S
After setting appropriate gates with the E
¡'low cytometric analysis
From one patient the initial ken 
contain exclusively the most s
is. Therefore, flow c
fidai layers of the
assessment was
performed on 76 epidermal cell suspensions obtained 
from test 
cells per si
±  standard error of mean) was 78-1 ±  1*2 (range 
48*7-93*5). The clinical scores and the flow cytometric
s of 38 patients. The percentage of in tact 
(corrected for debris and clumps) (mean
((’) 19%  British Association of Dermatologists, British Journal of Iknnatolomi, l ì  5, 579- î 84
382 C.P.GLADE etcil.
analyses of till biopsies before and after treatment; are 
shown in. Figure 1. It can be seen that the percentage of
clinical 
0-26,
vimentin-positive correlates with
expression of inflammation, i.e. erythema (r
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Figure 1. Correlation of d in  ini I scorns and How cytometric' analyses 
(means i  SIvM) orall test lesions (/i =  7(i). (a) PercenLagos of vlmentin 
positive cells vs. erythema score, (b) Percentages of keratin 10 positive 
keratinocyles vs. ciesqunmallon score, (c) PercenUiges of basal kera- 
tinocytes in S- and (oM -phase vs. induration score.
P <  0-05), that relative of keratin 10
positive keratinocytes (differentiation) correlates inver-
with the score for amation (i 0-40,
P <  (.)•(.) 1), and that the percentage of basal keratino-
ation) correlicytes in S- and (^M-phase
with the induration score of the psoriatic test
(r =  0*5 3, P <  0-0001) .
Table 1 summarizes the expression of the markers for
ition and inflammation before and
treatment. All 
daily application of e<
apy reg '.e
in a statistically 
ige of basal keratino-significant decrease of 
cytes in S- and GjM-phase. Following ci 
daily and twice daily the reductions of this parameter 
were 24% (P ~  0-24) and 34% (P <  0-05), respectively,
treatment with calcipo- 
triol/clobetasone 17-butyrate and calcipotriol/beta- 
methasone 17-valerate were 44% (P <  0-01) and 47% 
(P < 0-01), respectively. With respect to the number of 
vimentin-positive cells a statistically significant decrease 
was reached in the calcipotriol/clobetasone butyrate 
treated group (47%, P < 0-05). Values for the other 
therapy groups were 29% (P — 0*19) for 
betamethasone, 21% (P = 0-34) for 
daily and 23% (P =  0'42) for
of differentiated kerati 
increased in all therapy 
jance was only reached with calci 
butyrate (35%, P < (M)5).
twice daily, 
s (keratin 10
s. Statistical sig-
From the present flow cytometric evaluation the follow­
ing conclusions were drawn: (i) twice daily treatment 
with calcipotriol cream results in a substantial decrease 
of the percentage of cells in S- and CjM-phase in 
basal cell layer, without a significant effect on the 
percentage of vimentin cells; (ii) once daily 
cream does not result in a 
significant reduction of the percentage of cells in S- and 
GuVl-phase in the basal cell layer; (iii) combination of
tnd topical steroids results in a more marked 
decrease of the epidermal proliferative activity compared 
with calcipotriol treatment; (iv) a marked reduction of
of vimentin cells is observed
the concurrent use of calcipotriol and topical
apy has virtuallyireas caie
no
rete
on s nié
of
; and (v) an increase of the
is
concur use of calcipotriol and
n  19% British Association olVDermatologl.sls, British ¡ounuil ojDminitohniii, 1 ÌS, 579 5X4
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Vimentin Keratin 1(3 8 and G > M
--- —i*-. .i.r».- . w . -  ------ - « i  » « J , . .J. t *  i*.
Be lf" After treatment Ba?" After treatment Baseline or Irei
»nee daily 
twice daily
î lasone
17-butyrate
Calcipotriol/belamelhasone 
17-valerate
n
n
n
n
9 .10-8 ±  2-0 8-5 ±  1-0 41-0  ±  5*3 50*2 ±  3-9 14' 1 ±  2\3
ft. Ml * uw  — im 
10*8 i 2*2
9 10-9 ± 2*2 8-4 ± 1 - 1 44*3 ±  4*4 54' 3 d: 4*1 15*2 i  .1*2 1.0*1 ± 1-9*
9 14-4 ±  1-8 7-8 ±  0-8* 55-7 i. 3-3 48*2 ±  5-3* 16*1 ± 2 * 5 8*9 ± 1-0**
11 15*5 ±  2*8 10-7 ±  1-5 37-9 .1: 4-2 40-5  ±  3-1 16-5 ±  2 ' J 8*7 1.. 1*3**
m m m
*/** Significant differences (compared with baseline) at the P <  0-05 and P < (K )l level, respectively
In the present study the effect of the different treat-
ment schedules was assessed using flow cytometric 
quantilication of epidermal growth, and of markers fol­
iation and inflammation. These markers were 
chosen in analogy to the clinical features of the psoriatic 
lesion, i.e. erythema, induration and desquamation that 
are assessed in the PASI score. In previous studies the 
methodology was evaluated in epidermal hyperpro­
liferation induced by sellotape stripping,2(1 after appli-
cation of leukotriene B4 to normal skin27 and in
psoriatic patients before and following treatment. i , In
Figure 1 the correlation between the percentage of basal 
cells in S- and G2M-phase and induration, between the
Me
percentage of vimentin-positive cells and erythema, and 
between the percentage of keratin 10 positive keratino- 
cytes and scaling further substantiates the relationship 
between clinical features of the psoriatic lesion and the 
cell biological equivalent.
In a previous immunohistoehemieal study it was 
shown that calcipotriol ointment twice daily had a 
minor effect on cutaneous inflammation.9 In a recent 
study using the same flow cytometric analytical
it was shown that Tacalcitof (lr*,24 dihydroxy- 
vitamin l)j, 4//.g/g) ointment, applied once daily, had 
a substantial effect on epidermal proliferation (34% 
reduction of the percentage basal keratinocytes in S- 
and (ijM-phase) without a signillcant effect on the
of vimentin-positive cells.21 The presentp e r e »
on calcipotriol demonstrates a similar preponder­
ance of the antiproliferative effect. As once daily treat­
ment with calcipotriol cream had a minor effect on 
epidermal growth of the psoriatic lesion, twice daily 
application seems to be a more optimal approach.
Insight into the in vivo action of antipsoriatic treat­
ments helps to 
The present s
e promising c schedules.
indicates that concurrent use of 
and a topical corticosteroid has a more
animation,
on epidermal hyperproliferation and 
ared with monotherapy with calci- 
it is of interest that after clobeta- 
sol 17-propionate monotherapy, the reduction of the 
percentage of basal cells in S- and G^M-phase was 72% 
and the reduction of the percentage of vimentin positive 
was 62% (unpublished data). Surprisingly, a marked dif­
ference between both combination therapies was observed 
with respect to the expression of the differentiation- 
related keratin 1 0 : the increase after treatment with 
calcipotriol and clobetasone 17-butyrate was 35% and
following treatment with combination of calcipo-
triol and betamethasone I 7-valerate 7%.
In conclusion, the present flow cytometric study lends
sis that the effect of calcipotriol 
once daily is inferior to calcipotriol twice daily and that 
the combination of calcipotriol and a corticosteroid has 
a better antipsoriatic efficacy compared with calcipotriol 
monotherapy.
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